Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HTL 0016878

Next Previous
Search
Drug Profile

HTL 0016878

Alternative Names: HTL-0016878; NBI-1117568; NBI-568

Latest Information Update: 23 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heptares Therapeutics
  • Developer AbbVie; Neurocrine Biosciences; Nxera Pharma
  • Class Antidementias; Antipsychotics; Small molecules
  • Mechanism of Action Muscarinic M4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Schizophrenia
  • No development reported Alzheimer's disease

Most Recent Events

  • 14 Jan 2025 In January 2025, Neurocrine is expected to initiate a Phase II study with NBI 568 in bipolar mania in second half of 2025
  • 14 Jan 2025 Neurocrine Biosciences plans a phase III trial in Schizophrenia in first half of 2025
  • 28 Aug 2024 Efficacy and adverse events data from a phase II trial in Schizophrenia released by Neurocrine Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top